Whitehawk Therapeutics, Inc DEFA14A, filed Apr 27, 2020
Whitehawk Therapeutics, Inc. (WHWK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
|
|
|
|
☐ |
|
Preliminary Proxy Statement |
|
|
|
|
|
☐ |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
|
|
|
☐ |
|
Definitive Proxy Statement |
|
|
|
|
|
☒ |
|
Definitive Additional Materials |
|
|
|
|
|
☐ |
|
Soliciting Material under § 240.14a-12 |
Aerpio Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
|
|
|
|
|||
|
☒ |
|
No fee required |
||
|
|
|
|||
|
☐ |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11 |
||
|
|
|
|
||
|
|
|
(1) |
|
Title of each class of securities to which transaction applies:
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies:
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction:
|
|
|
|
(5) |
|
Total fee paid:
|
|
|
|
|||
|
☐ |
|
Fee paid previously with preliminary materials. |
||
|
|
|
|||
|
☐ |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by the registration statement number, or the Form or Schedule and the date of its filing. |
||
|
|
|
|
||
|
|
|
(1) |
|
Amount Previously Paid:
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.:
|
|
|
|
(3) |
|
Filing Party:
|
|
|
|
(4) |
|
Date Filed:
|
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders of AERPIO PHARMACEUTICALS, INC. To Be Held On: June 24, 2020 10:30 AM Eastern Time at 9987 Carver Road, Suite 420, Cincinnati, OH 45242 COMPANY NUMBER ACCOUNT NUMBER CONTROL NUMBER You cannot use this notice to vote by mail. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet or by mail. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you want to receive a paper or email copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before 6/12/20. Please visit http://www.astproxyportal.com/ast/21404/, where the following materials are available for view:• Notice of Annual Meeting of Stockholders • Proxy Statement • Form of Electronic Proxy Card • Annual Report on Form 10K TO REQUEST MATERIAL: TELEPHONE: 888ProxyNA (8887769962) 7189218562 (for international callers) EMAIL: info@astfinancial.com WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials TO VOTE: ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the onscreen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cutoff or meeting date. IN PERSON: You may vote your shares in person by attending the Annual Meeting. TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call. MAIL: You may request a card by following the instructions above. 1. To elect two Class III directors to hold office until the 2023 annual meeting of stockholders: NOMINEES: Joseph Gardner Steven Prelack 2. To approve a potential amendment to our Amended and Restated Certificate of Incorporation to effect a Reverse Stock Split of the Common Stock at a ratio within the range of 1for15 to 1for25, such ratio to be determined in the sole discretion of the Board of Directors. 3. To ratify the appointment of Ernst & Young LLP as Aerpio's independent registered public accounting firm for the fiscal year ending December 31, 2020. THE BOARD OF DIRECTORS RECOMMENDS YOU VOTE "FOR ALL NOMINEES" IN PROPOSAL 1 AND "FOR" PROPOSALS 2 AND 3.